Utilization and outcomes of low dose versus high dose cisplatin in head and neck cancer patients receiving concurrent radiation.

6019 Background: Although level I evidence supports the use of high dose (HD) intermittent cisplatin with concurrent RT for locally advanced head and neck squamous cell carcinoma (LA-HNSCC), low dose (LD) weekly cisplatin has been adopted, including in recently activated national clinical trials. We sought to examine patterns of care and outcomes of cisplatin in this setting using a US prospective observational registry. Methods: We utilized Longitudinal Oncology Registry of Head And Neck Carcinoma (LORHAN). Patients (pts) included in the analysis had newly diagnosed, stage III or IV, non-metastatic HNSCC, received RT and chemotherapy, were ≥ 18 years and had provided written informed consent. Pts were enrolled to the LORHAN Registry from 2005 to 2010, with data available through 2011. Propensity score weighting was applied to adjust for confounding in comparisons between dose groups. Results: 1,091 pts received cisplatin plus concurrent RT and were categorized by initial cisplatin dose received: LD (≤ 40...